Thymoquinone accelerates osteoblast differentiation and activates bone morphogenetic protein-2 and ERK pathway
- 1 February 2013
- journal article
- Published by Elsevier BV in International Immunopharmacology
- Vol. 15 (2), 381-386
- https://doi.org/10.1016/j.intimp.2012.12.033
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- The Clinical Use of Denosumab for the Management of Low Bone Mineral Density in Postmenopausal WomenJournal of Pharmacy Practice, 2012
- The chemical synthesis of metabolically stabilized 2-OMe-LPA analogues and preliminary studies of their inhibitory activity toward autotaxinBioorganic & Medicinal Chemistry Letters, 2012
- Update on Bone Anabolics in Osteoporosis Treatment: Rationale, Current Status, and PerspectivesJournal of Clinical Endocrinology & Metabolism, 2012
- Parathyroid Hormone versus Bisphosphonate Treatment on Bone Mineral Density in Osteoporosis Therapy: A Meta-Analysis of Randomized Controlled TrialsPLOS ONE, 2011
- The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal womenBMC Musculoskeletal Disorders, 2011
- Osteoporosis: impact on health and economicsNature Reviews Rheumatology, 2010
- Drug Insight: existing and emerging therapies for osteoporosisNature Clinical Practice Endocrinology & Metabolism, 2006
- Economic Implications of Hip Fracture: Health Service Use, Institutional Care and Cost in CanadaOsteoporosis International, 2001
- Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosisThe American Journal of Medicine, 1993
- Hip fractures in the elderly: A world-wide projectionOsteoporosis International, 1992